Federal Register: December 29, 2008 (Volume 73, Number 249)
DOCID: fr29de08-9 FR Doc E8-30694
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
CFR Citation: 21 CFR Part 524
Docket ID: [Docket No. FDA-2008-N-0039]
NOTICE: RULES
DOCID: fr29de08-9
ACTION: Ophthalmic and Topical Dosage Form New Animal Drugs:
DOCUMENT ACTION: Final rule.
SUBJECT CATEGORY:
Ophthalmic and Topical Dosage Form New Animal Drugs; Triamcinolone Cream
DATES: This rule is effective December 29, 2008.
DOCUMENT SUMMARY:
The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of an abbreviated new animal drug application (ANADA) filed by Modern Veterinary Therapeutics, LLC. The ANADA provides for veterinary prescription use of triamcinolone cream on dogs for topical treatment of allergic dermatitis and summer eczema.
SUMMARY:
Triamcinolone Cream,
SUPPLEMENTAL INFORMATION
Modern Veterinary Therapeutics, LLC, 1550
Madruga Ave., suite 329, Coral Gables, FL 33146, filed ANADA 200459 that provides for veterinary prescription use of VETAZINE
(triamcinolone acetonide) Cream on dogs for topical treatment of
allergic dermatitis and summer eczema. Modern Veterinary Therapeutics,
LLC's VETAZINE Cream is approved as a generic copy of VETALOG Cream,
sponsored by Fort Dodge Animal Health, A Division of Wyeth Holdings
Corp., under NADA 46146. The ANADA is approved as of November 13,
2008, and the regulations are amended in Sec. 524.2481 to reflect the approval.
In accordance with the freedom of information provisions of 21 CFR part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Division of Dockets Management (HFA305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.
The agency has determined under 21 CFR 25.33(a)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.
This rule does not meet the definition of ``rule'' in 5 U.S.C.
804(3)(A) because it is a rule of ``particular applicability.''
Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801808.
List of Subjects in 21 CFR Part 522
Animal drugs.
Therefore, under the Federal Food, Drug, and Cosmetic Act and under
authority delegated to the Commissioner of Food and Drugs and
redelegated to the Center for Veterinary Medicine, 21 CFR part 524 is amended as follows:
PART 524OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS
1. The authority citation for 21 CFR part 524 continues to read as follows:
Authority: 21 U.S.C. 360b.
2. In Sec. 524.2481, revise paragraphs (b), (c)(2), and (c)(3) to read as follows:
Sec. 524.2481 Triamcinolone cream.
* * * * *
(b) Sponsor. See Nos. 015914, 053501, and 054925 in Sec. 510.600(c) of this chapter.
(c) * * *
(2) Indications for use. For topical treatment of allergic dermatitis and summer eczema.
(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Dated: December 18, 2008.
William T. Flynn,
Acting Director, Center for Veterinary Medicine.
[FR Doc. E830694 Filed 122408; 8:45 am]
BILLING CODE 416001S
FOR FURTHER INFORMATION CONTACT
John K. Harshman, Center for
Veterinary Medicine (HFV104), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 2402768197, email:
john.harshman@fda.hhs.gov.